SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-026214
Filing Date
2018-11-01
Accepted
2018-11-01 16:04:33
Documents
53
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-10q_20180930.htm 10-Q 1857201
2 EX-10.1 fate-ex101_83.htm EX-10.1 176788
3 EX-10.2 fate-ex102_114.htm EX-10.2 7707876
4 EX-31.1 fate-ex311_8.htm EX-31.1 9963
5 EX-32.1 fate-ex321_9.htm EX-32.1 4818
6 GRAPHIC g1yicldrme22000001.jpg GRAPHIC 6712
  Complete submission text file 0001564590-18-026214.txt   15536893

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT fate-20180930.xml EX-101.INS 1859670
8 XBRL TAXONOMY EXTENSION SCHEMA fate-20180930.xsd EX-101.SCH 56415
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fate-20180930_cal.xml EX-101.CAL 46691
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fate-20180930_def.xml EX-101.DEF 226276
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20180930_lab.xml EX-101.LAB 426597
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20180930_pre.xml EX-101.PRE 319781
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 181153673
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1